Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The FDA intends to place a black box label—its most serious warning—on COVID-19 vaccines, according to reporting by CNN. It ...

On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...

Shares of Novavax fell more than 25% in after-hours trading Tuesday, following a dismal fourth quarter earnings report and a warning from the Covid vaccine maker that uncertainty over future funding ...

Five weeks into his job as the new CEO as Novavax, John Jacobs raised the possibility on Tuesday afternoon that the company may not survive 2023. “Uncertainty,” was used often during Novavax’s fourth ...

Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...

Novavax (NVAX-0.94%) stock is up around 3,500% so far this year. And that's after a significant recent decline. Earlier this month, shares of Novavax were up nearly 4,400% year to date. These ...

Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other common vaccines, including those for influenza and shingles.

Novavax is throwing marketing muscle behind its bid to capture a piece of the fall COVID-19 booster vaccine market. Having seen mRNA vaccines dominate the market, the biotech wants the public to know ...

The Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and ...

Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its ...